within Pharmacolibrary.Drugs.ATC.D;

model D10AF05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.02,
    Cl             = 0.0,
    adminDuration  = 600,
    adminMass      = 0.01,
    adminCount     = 1,
    Vd             = 0,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Nadifloxacin is a topical fluoroquinolone antibiotic primarily used for the treatment of acne vulgaris and skin infections due to susceptible bacteria. It is not widely approved in many countries but is available in some regions, notably in Japan and parts of Asia. Nadifloxacin is generally applied as a topical cream and is not used systemically.</p><h4>Pharmacokinetics</h4><p>No systemic pharmacokinetic parameters have been published for nadifloxacin in humans following topical administration, as systemic absorption is minimal. Published data focus on dermal application in healthy adults for dermatological conditions.</p><h4>References</h4><ol><li><p>Jacobs, MR, &amp; Appelbaum, PC (2006). Nadifloxacin: a quinolone for topical treatment of skin infections and potential for systemic use of its active isomer, WCK 771. <i>Expert opinion on pharmacotherapy</i> 7(14) 1957–1966. DOI:<a href=&quot;https://doi.org/10.1517/14656566.7.14.1957&quot;>10.1517/14656566.7.14.1957</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17020421/&quot;>https://pubmed.ncbi.nlm.nih.gov/17020421</a></p></li><li><p>Herbert, R, et al., &amp; Kaye, SB (2022). Potential new fluoroquinolone treatments for suspected bacterial keratitis. <i>BMJ open ophthalmology</i> 7(1) –. DOI:<a href=&quot;https://doi.org/10.1136/bmjophth-2022-001002&quot;>10.1136/bmjophth-2022-001002</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36161851/&quot;>https://pubmed.ncbi.nlm.nih.gov/36161851</a></p></li><li><p>Kuwahara, K, et al., &amp; Kikuchi, M (2005). Nadifloxacin, an antiacne quinolone antimicrobial, inhibits the production of proinflammatory cytokines by human peripheral blood mononuclear cells and normal human keratinocytes. <i>Journal of dermatological science</i> 38(1) 47–55. DOI:<a href=&quot;https://doi.org/10.1016/j.jdermsci.2005.01.002&quot;>10.1016/j.jdermsci.2005.01.002</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15795123/&quot;>https://pubmed.ncbi.nlm.nih.gov/15795123</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end D10AF05;
